# Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

> **NCT05737303** · PHASE3 · RECRUITING · sponsor: **Women's Hospital School Of Medicine Zhejiang University** · enrollment: 538 (estimated)

## Conditions studied

- Epithelial Ovarian Carcinoma Stage III
- Epithelial Ovarian Carcinoma Stage IV
- Fallopian Tube Carcinoma Stage III
- Fallopian Tube Carcinoma Stage IV
- Primary Peritoneal Carcinoma Stage III
- Primary Peritoneal Carcinoma Stage IV

## Interventions

- **DRUG:** nab-paclitaxel combined with carboplatin

## Key facts

- **NCT ID:** NCT05737303
- **Lead sponsor:** Women's Hospital School Of Medicine Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 538 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737303, "Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05737303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*